Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MCL1 | Q07820 | 6/20 | 0.71 |
| ▸ | RXFP1 | Q9HBX9 | 3/20 | 0.71 |
| ▸ | BCKDK | O14874 | 2/20 | 0.71 |
| ▸ | GPR35 | Q9HC97 | 1/20 | 0.58 |
| ▸ | BCL2L1 | Q07817 | 3/20 | 0.58 |
| ▸ | BCL2 | P10415 | 2/20 | 0.53 |
| ▸ | BAD | Q92934 | 2/20 | 0.53 |
| ▸ | NPC1 | O15118 | 3/20 | 0.50 |
| ▸ | RAB9A | P51151 | 3/20 | 0.50 |
| ▸ | TBXAS1 | P24557 | 2/20 | 0.49 |
| ▸ | PKM | P14618 | 1/20 | 0.47 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.46 |
| ▸ | MAPT | P10636 | 2/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.45 |
| ▸ | PRNP | P04156 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | F10 | P00742 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL121901 | 0.87 | MCL1 (0.57) | MCL1RXFP1BCKDKGPR35BCL2L1 | |
| SCHEMBL122587 | 0.87 | GPR35 (0.58) | MCL1RXFP1BCKDKGPR35BCL2L1 | |
| SCHEMBL6886010 | 0.83 | MCL1 (1.00) | MCL1RXFP1BCKDKBCL2L1BCL2 | |
| SCHEMBL15619574 | 0.83 | MCL1 (0.71) | MCL1RXFP1BCKDKGPR35BCL2L1 | |
| SCHEMBL15619136 | 0.83 | MCL1 (0.53) | MCL1RXFP1BCKDKBCL2L1BCL2 | |
| Hydrochloric Acid SCHEMBL11394582 | 0.81 | MCL1 (0.97) | MCL1RXFP1BCKDKBCL2L1BCL2 | |
| SCHEMBL3680399 | 0.80 | MCL1 (0.50) | MCL1RXFP1BCKDKBCL2L1BCL2 | |
| SCHEMBL2895162 | 0.80 | BCKDK (0.67) | MCL1RXFP1BCKDKGPR35BCL2L1 | |
| SCHEMBL2895958 | 0.80 | GPR35 (0.58) | MCL1RXFP1BCKDKGPR35BCL2L1 | |
| SCHEMBL11684474 | 0.80 | MCL1 (0.71) | MCL1RXFP1BCKDKBCL2L1BCL2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4709480-A1 | 5,6-FUSED BICYCLIC AMIDES AND COMPOSITIONS FOR USE AS 15-PROSTAGLANDIN DEHYDROGENASE MODULATORS | Amgen Inc. (US) | 2026-03-18 | — | — | EP | disclosed |
| US-10844032-B2 | Substituted benzofuran, benzothiophene and indole Mcl-1 inhibitors | VANDERBILT UNIVERSITY (US) | 2020-11-24 | — | — | US | disclosed |
| US-10759769-B2 | Glucosylceramide synthase inhibitors for the treatment of diseases | BIOMARIN PHARMECEUTICAL INC (US) | 2020-09-01 | — | — | US | disclosed |
| US-20190248754-A1 | GLUCOSYLCERAMIDE SYNTHASE INHIBITORS FOR THE TREATMENT OF DISEASES | BIOMARIN PHARMECEUTICAL INC (US) | 2019-08-15 | — | — | US | disclosed |
| EP-3268355-B1 | GLUCOSYLCERAMIDE SYNTHASE INHIBITORS FOR THE TREATMENT OF DISEASES | BIOMARIN PHARM INC (US) | 2019-06-12 | — | — | EP | disclosed |
| US-10227312-B2 | Glucosylceramide synthase inhibitors for the treatment of diseases | BIOMARIN PHARMACEUTICAL INC. (US) | 2019-03-12 | — | — | US | disclosed |
| US-20180312485-A1 | SUBSTITUTED BENZOFURAN, BENZOTHIOPHENE AND INDOLE MCL-1 INHIBITORS | VANDERBILT UNIVERSITY | 2018-11-01 | — | — | US | disclosed |
| US-10093640-B2 | Substituted benzofuran, benzothiophene and indole MCL-1 inhibitors | VANDERBILT UNIVERSITY (US) | 2018-10-09 | — | — | US | disclosed |
| EP-3365061-A1 | AMINOISOXAZOLINE COMPOUNDS AS AGONISTS OF ALPHA7-NICOTINIC ACETYLCHOLINE RECEPTORS | Axovant Sciences GmbH (DE) | 2018-08-29 | — | — | EP | disclosed |
| US-20180044302-A1 | GLUCOSYLCERAMIDE SYNTHASE INHIBITORS FOR THE TREATMENT OF DISEASES | BIOMARIN PHARMACEUTICAL INC. | 2018-02-15 | — | — | US | disclosed |
| US-20170247393-A1 | Aminoisoxazoline Compounds as Agonists of Alpha7-Nicotinic Acetylcholine Receptors | FORUM PHARMACEUTICALS, INC. | 2017-08-31 | — | — | US | disclosed |
| US-20170247393-A1 | Aminoisoxazoline Compounds as Agonists of Alpha7-Nicotinic Acetylcholine Receptors | FORUM PHARMACEUTICALS, INC. | 2017-08-31 | — | — | US | disclosed |
| US-20170247393-A1 | Aminoisoxazoline Compounds as Agonists of Alpha7-Nicotinic Acetylcholine Receptors | FORUM PHARMACEUTICALS, INC. | 2017-08-31 | — | — | US | disclosed |
| WO-2017069980-A1 | AMINOISOXAZOLINE COMPOUNDS AS AGONISTS OF ALPHA7-NICOTINIC ACETYLCHOLINE RECEPTORS | FORUM PHARMACEUTICALS, INC. (US) | 2017-04-27 | — | — | WO | disclosed |
| WO-2017069980-A1 | AMINOISOXAZOLINE COMPOUNDS AS AGONISTS OF ALPHA7-NICOTINIC ACETYLCHOLINE RECEPTORS | FORUM PHARMACEUTICALS, INC. (US) | 2017-04-27 | — | — | WO | disclosed |
| WO-2016145153-A1 | GLUCOSYLCERAMIDE SYNTHASE INHIBITORS FOR THE TREATMENT OF DISEASES | BIOMARIN PHARMACEUTICAL INC. (US) | 2016-09-15 | — | — | WO | disclosed |
| US-20150336925-A1 | SUBSTITUTED BENZOFURAN, BENZOTHIOPHENE AND INDOLE MCL-1 INHIBITORS | VANDERBILT UNIVERSITY (US) | 2015-11-26 | — | — | US | disclosed |
| WO-2014047427-A2 | SUBSTITUTED BENZOFURAN, BENZOTHIOPHENE AND INDOLE MCL-1 INHIBITORS | VANDERBILT UNIVERSITY (US) | 2014-03-27 | — | — | WO | disclosed |
| US-8048901-B2 | 5-{3-[3-(5-Methyl-2-m-tolyloxazol-4-ylmethoxy)cyclohexyloxy]-propyl}-2H-tetrazole; metabolic disorders, insulin resistance, dyslipidemia, Syndrome X | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2011-11-01 | — | — | US | disclosed |
| US-20080249126-A1 | 1,3-SUBSTITUTED CYCLOALKYL DERIVATIVES HAVING ACIDIC, MOSTLY HETEROCYCLIC GROUPS, PROCESSES FOR THEIR PREPARATION AND THEIR USE AS PHARMACEUTICALS | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2008-10-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170247393-A1 | Aminoisoxazoline Compounds as Agonists of Alpha7-Nicotinic Acetylcholine Receptors | CHRNA7, CHRNA5, CHRNA2 | MCL1 4862/4885RXFP1 285/4885BCKDK 3528/4885 |
| US-20080249126-A1 | 1,3-SUBSTITUTED CYCLOALKYL DERIVATIVES HAVING ACIDIC, MOSTLY HETEROCYCLIC GROUPS, PROCESSES FOR THEIR PREPARATION AND THEIR USE AS PHARMACEUTICALS | GPR119, PC, FFAR1 | MCL1 2050/4885RXFP1 2358/4885BCKDK 57/4885 |
| US-20180312485-A1 | SUBSTITUTED BENZOFURAN, BENZOTHIOPHENE AND INDOLE MCL-1 INHIBITORS | MCL1, BCL2L1, BCLAF1 | MCL1 1/4885RXFP1 4672/4885BCKDK 3122/4885 |
| US-20150336925-A1 | SUBSTITUTED BENZOFURAN, BENZOTHIOPHENE AND INDOLE MCL-1 INHIBITORS | MCL1, BCL2L1, BCLAF1 | MCL1 1/4885RXFP1 4672/4885BCKDK 3122/4885 |
| US-10759769-B2 | Glucosylceramide synthase inhibitors for the treatment of diseases | GBA1, UGCG, GBA2 | MCL1 2251/4885RXFP1 4460/4885BCKDK 2034/4885 |
| US-20180044302-A1 | GLUCOSYLCERAMIDE SYNTHASE INHIBITORS FOR THE TREATMENT OF DISEASES | GBA1, UGCG, GBA2 | MCL1 2251/4885RXFP1 4460/4885BCKDK 2034/4885 |
| US-10093640-B2 | Substituted benzofuran, benzothiophene and indole MCL-1 inhibitors | MCL1, BCL2L1, BCLAF1 | MCL1 1/4885RXFP1 4672/4885BCKDK 3122/4885 |
| US-20190248754-A1 | GLUCOSYLCERAMIDE SYNTHASE INHIBITORS FOR THE TREATMENT OF DISEASES | GBA1, UGCG, GBA2 | MCL1 2251/4885RXFP1 4460/4885BCKDK 2034/4885 |
| US-10227312-B2 | Glucosylceramide synthase inhibitors for the treatment of diseases | GBA1, UGCG, GBA2 | MCL1 2251/4885RXFP1 4460/4885BCKDK 2034/4885 |
| US-10844032-B2 | Substituted benzofuran, benzothiophene and indole Mcl-1 inhibitors | MCL1, BCL2L1, BCLAF1 | MCL1 1/4885RXFP1 4672/4885BCKDK 3122/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.